The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Adaptive Biotechnologies and Pfizer enter two significant partnerships worth up to $890 million for T-cell receptor research and AI drug discovery.
Dec 15, 2025•6 months ago
Contract Type
partnership
SeattleBiotechnologyHealth CareTherapeutics
Description
Adaptive Biotechnologies has secured two agreements with Pfizer that could yield up to $890 million, focusing on T-cell receptor research for rheumatoid arthritis and AI applications. These partnerships validate Adaptive's technology platform and enable them to concentrate on target discovery, while Pfizer manages development and commercialization.
Company Information
Company
Adaptive Biotechnologies Corporation
Location
Seattle, Washington, United States
About
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the adaptive immune system's biology to transform disease diagnosis and treatment. They develop clinical products aimed at diagnosing and treating diseases using advanced genetic techniques. Their flagship product, clonoSEQ®, is designed to detect minimal residual disease in various blood cancers. The company's innovative approach seeks to provide precise and effective solutions in the field of hematology.
Predictive Intelligence
Strategic
ML-powered predictions for Adaptive Biotechnologies Corporation's next move
SeattleBiotechnologyHealth CareTherapeutics